Melanoma: Risk factors, early detection, and treatment strategies-An updated review

Sahar Adi Albogamy; ‏Maram Jaafar Alnemer; ‏Hussain Mahdi Aljawad; Alaa Saud K Alanazi; ‏Abdulalah Thabet Alharbi; Mohammed Saad Ali Al-Harbi; Sultan Mohammed Algfari

doi:10.53730/ijhs.v7nS1.15239

Authors

Sahar Adi Albogamy KSA, National Guard Health Affairs
‏Maram Jaafar Alnemer KSA, National Guard Health Affairs
‏Hussain Mahdi Aljawad KSA, National Guard Health Affairs
Alaa Saud K Alanazi KSA, National Guard Health Affairs
‏Abdulalah Thabet Alharbi KSA, National Guard Health Affairs
Mohammed Saad Ali Al-Harbi KSA, National Guard Health Affairs
Sultan Mohammed Algfari KSA, National Guard Health Affairs

Keywords:

Melanoma, skin cancer, early detection, treatment strategies, nanotechnology

Abstract

Background: Melanoma is a significant and aggressive form of skin cancer originating from melanocytes. The rising incidence of melanoma, particularly among younger populations, underscores the need for increased awareness and early detection. Aim: This review aims to provide a comprehensive overview of the risk factors, early detection methods, and treatment strategies for melanoma, emphasizing recent advancements in the field. Methods: The review synthesizes current literature regarding melanoma's epidemiology, etiology, clinical presentation, diagnostic techniques, and therapeutic approaches. Emphasis is placed on advancements in immunotherapy, targeted therapies, and emerging nanotechnology-based strategies. Results: The global incidence of melanoma is increasing, with environmental factors such as UV radiation being the primary modifiable risk factor. Innovative treatment options, including immune checkpoint inhibitors and small-molecule kinase inhibitors, have shown promising results, although challenges such as drug resistance and adverse side effects remain. Recent clinical trials indicate that combination therapies may enhance treatment efficacy. Nanotechnology has emerged as a valuable tool for improving drug delivery and targeting tumor sites effectively. Conclusion: Melanoma poses a serious public health challenge due to its aggressive nature and rising incidence. Early detection through routine skin examinations and awareness of risk factors is crucial for improving outcomes.

Downloads

Download data is not yet available.

References

Gilaberte, Y.; Prieto-Torres, L.; Pastushenko, I.; Juarranz, Á. Anatomy and Function of the Skin. In Nanoscience in Dermatology; Hamblin, M.R., Avci, P., Prow, T.W., Eds.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 1–14. ISBN 978-0-12-802926-8. DOI: https://doi.org/10.1016/B978-0-12-802926-8.00001-X

Park, S. Biochemical, structural and physical changes in aging human skin, and their relationship. Biogerontology 2022, 23, 275–288. DOI: https://doi.org/10.1007/s10522-022-09959-w

Thakur, R.; Batheja, P.; Kaushik, D.; Michniak, B. Structural and Biochemical Changes in Aging Skin and Their Impact on Skin Permeability Barrier. In Skin Aging Handbook; Dayan, N., Ed.; Elsevier: Amsterdam, The Netherlands, 2009; pp. 55–90. ISBN 978-0-8155-1584-5. DOI: https://doi.org/10.1016/B978-0-8155-1584-5.50008-9

Mota, A.H.; Rijo, P.; Molpeceres, J.; Reis, C.P. Broad overview of engineering of functional nanosystems for skin delivery. Int. J. Pharm. 2017, 532, 710–728. DOI: https://doi.org/10.1016/j.ijpharm.2017.07.078

Lim, H.W.; Collins, S.A.B.; Resneck, J.S.; Bolognia, J.L.; Hodge, J.A.; Rohrer, T.A.; Van Beek, M.J.; Margolis, D.J.; Sober, A.J.; Weinstock, M.A.; et al. The burden of skin disease in the United States. J. Am. Acad. Dermatol. 2017, 76, 958–972.e2. DOI: https://doi.org/10.1016/j.jaad.2016.12.043

Basra, M.K.; Shahrukh, M. Burden of skin diseases. Expert Rev. Pharmacoecon. Outcomes Res. 2014, 9, 271–283. DOI: https://doi.org/10.1586/erp.09.23

Richard, M.A.; Paul, C.; Nijsten, T.; Gisondi, P.; Salavastru, C.; Taieb, C.; Trakatelli, M.; Puig, L.; Stratigos, A. Prevalence of most common skin diseases in Europe: A population-based study. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1088–1096. DOI: https://doi.org/10.1111/jdv.18050

International Agency for Research on Cancer Cancer Tomorrow. Estimated Number of New Cases from 2020 to 2040 of Melanoma of Skin and Non-Melanoma Skin Cancer.

International Agency for Research on Cancer Cancer Tomorrow. Estimated Number of Deaths from 2020 to 2040 of Melanoma of Skin and Non-Melanoma Skin Cancer

Euro Melanoma and Global Coaliation for Melanoma Patient Advocacy. 2020 Melanoma Skin Cancer Report: Stemming the Global Epidemic; Global Coalition for Melanoma Patient Advocacy: Oldham, UK, 2020.

Linares, M.A.; Zakaria, A.; Nizran, P. Skin Cancer. Prim. Care 2015, 42, 645–659. DOI: https://doi.org/10.1016/j.pop.2015.07.006

Lai, V.; Cranwell, W.; Sinclair, R. Epidemiology of skin cancer in the mature patient. Clin. Dermatol. 2018, 36, 167–176 DOI: https://doi.org/10.1016/j.clindermatol.2017.10.008

Rebecca, V.W.; Sondak, V.K.; Smalley, K.S.M. A brief history of melanoma: From mummies to mutations. Melanoma Res. 2012, 22, 114–122. DOI: https://doi.org/10.1097/CMR.0b013e328351fa4d

Matthews, N.H.; Li, W.-Q.; Qureshi, A.A.; Weinstock, M.A.; Cho, E. Epidemiology of Melanoma. In Cutaneous Melanoma, Etiology and Therapy; Ward, W.H., Farma, J.M., Eds.; Codon Publications: Brisbane, Australia, 2017; pp. 139–149. ISBN 978-0-9944381-4-0.

Dimitriou, F.; Krattinger, R.; Ramelyte, E.; Barysch, M.J.; Micaletto, S.; Dummer, R.; Goldinger, S.M. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. Curr. Oncol. Rep. 2018, 20, 87. DOI: https://doi.org/10.1007/s11912-018-0732-8

Sommer, L. Generation of melanocytes from neural crest cells. Pigment. Cell Melanoma Res. 2011, 24, 411–421. DOI: https://doi.org/10.1111/j.1755-148X.2011.00834.x

D’Mello, S.A.N.; Finlay, G.J.; Baguley, B.C.; Askarian-Amiri, M.E. Signaling pathways in melanogenesis. Int. J. Mol. Sci. 2016, 17, 1144. DOI: https://doi.org/10.3390/ijms17071144

Caksa, S.; Baqai, U.; Aplin, A.E. The future of targeted kinase inhibitors in melanoma. Pharmacol. Ther. 2022, 239, 108200. DOI: https://doi.org/10.1016/j.pharmthera.2022.108200

Cichorek, M.; Wachulska, M.; Stasiewicz, A. Heterogeneity of neural crest-derived melanocytes. Cent. Eur. J. Biol. 2013, 8, 315–330. DOI: https://doi.org/10.2478/s11535-013-0141-1

Baroni, A.; Buommino, E.; De Gregorio, V.; Ruocco, E.; Ruocco, V.; Wolf, R. Structure and function of the epidermis related to barrier properties. Clin. Dermatol. 2012, 30, 257–262. DOI: https://doi.org/10.1016/j.clindermatol.2011.08.007

Carr, S.; Smith, C.; Wernberg, J. Epidemiology and Risk Factors of Melanoma. Surg. Clin. N. Am. 2020, 100, 1–12. DOI: https://doi.org/10.1016/j.suc.2019.09.005

Davey, M.G.; Miller, N.; McInerney, N.M. A Review of Epidemiology and Cancer Biology of Malignant Melanoma. Cureus 2021, 13, e15087. DOI: https://doi.org/10.7759/cureus.15087

Pérez-Guijarro, E.; Day, C.P.; Merlino, G.; Zaidi, M.R. Genetically engineered mouse models of melanoma. Cancer 2017, 123, 2089–2103. DOI: https://doi.org/10.1002/cncr.30684

Garbe, C.; Peris, K.; Hauschild, A.; Saiag, P.; Middleton, M.; Bastholt, L.; Grob, J.-J.; Malvehy, J.; Newton-Bishop, J.; Stratigos, A.J.; et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—Update 2016. Eur. J. Cancer 2016, 63, 201–217. DOI: https://doi.org/10.1016/j.ejca.2016.05.005

Millet, A.; Martin, A.R.; Ronco, C.; Rocchi, S.; Benhida, R. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Med. Res. Rev. 2017, 37, 98–148. DOI: https://doi.org/10.1002/med.21404

Garbe, C.; Amaral, T.; Peris, K.; Hauschild, A.; Arenberger, P.; Bastholt, L.; Bataille, V.; del Marmol, V.; Dréno, B.; Fargnoli, M.C.; et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics—Update 2019. Eur. J. Cancer 2020, 126, 141–158. DOI: https://doi.org/10.1016/j.ejca.2019.11.014

Ciążyńska, M.; Kamińska-Winciorek, G.; Lange, D.; Lewandowski, B.; Reich, A.; Sławińska, M.; Pabianek, M.; Szczepaniak, K.; Hankiewicz, A.; Ułańska, M.; et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci. Rep. 2021, 11, 1–10. DOI: https://doi.org/10.1038/s41598-021-94435-7

Leiter, U.; Eigentler, T.; Garbe, C. Epidemiology of Skin Cancer. In Sunlight, VitaminD and Skin Cancer; Reichrath, J., Ed.; Springer: New York, NY, USA, 2014; pp. 120–140. ISBN 978-1-4939-0437-2. DOI: https://doi.org/10.1007/978-1-4939-0437-2_7

Gupta, A.K.; Bharadwaj, M.; Mehrotra, R. Skin Cancer Concerns in People of Color: Risk Factors and Prevention. Asian Pac. J. Cancer Prev. 2016, 17, 5257.

Zambrano-Román, M.; Padilla-Gutiérrez, J.R.; Valle, Y.; Muñoz-Valle, J.F.; Valdés-Alvarado, E. Non-Melanoma Skin Cancer: A Genetic Update and Future Perspectives. Cancers 2022, 14, 2371. DOI: https://doi.org/10.3390/cancers14102371

Mozzillo, N.; Ascierto, P.A. Melanoma: The role of surgery in the era of new therapies. J. Transl. Med. 2014, 12, 195. DOI: https://doi.org/10.1186/1479-5876-12-195

Kozar, I.; Margue, C.; Rothengatter, S.; Haan, C.; Kreis, S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim. Biophys. Acta Rev. Cancer 2019, 1871, 313–322. DOI: https://doi.org/10.1016/j.bbcan.2019.02.002

Ostrowski, S.M.; Fisher, D.E. Biology of Melanoma. Hematol. Oncol. Clin. N. Am. 2021, 35, 29–56. DOI: https://doi.org/10.1016/j.hoc.2020.08.010

Matias, M.; Pinho, J.O.; Penetra, M.J.; Campos, G.; Reis, C.P.; Gaspar, M.M. The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval. Cells 2021, 10, 3088. DOI: https://doi.org/10.3390/cells10113088

Pinho, J.O.; Lopes, J.; Albino, M.; Reis, C.; Matias, M.; Gaspar, M.M. Advances in Nanotechnology-Related Strategies Against Melanoma. In Mitochondrial Dysfunction and Nanotherapeutics; de Oliveira, M.R., Ed.; Academic Press: Cambridge, MA, USA, 2021; pp. 385–424. ISBN 978-0-323-85666-9. DOI: https://doi.org/10.1016/B978-0-323-85666-9.00009-7

Silva, C.O.; Pinho, J.O.; Lopes, J.M.; Almeida, A.J.; Gaspar, M.M.; Reis, C. Current trends in cancer nanotheranostics: Metallic, polymeric, and lipid-based systems. Pharmaceutics 2019, 11, 22. DOI: https://doi.org/10.3390/pharmaceutics11010022

Halwani, A.A. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Pharmaceutics 2022, 14, 106. DOI: https://doi.org/10.3390/pharmaceutics14010106

Lopes, J.; Rodrigues, C.M.P.; Gaspar, M.M.; Reis, C.P. How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT. Pharmaceutics 2022, 14, 1817. DOI: https://doi.org/10.3390/pharmaceutics14091817

Bayda, S.; Adeel, M.; Tuccinardi, T.; Cordani, M.; Rizzolio, F. The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules 2020, 25, 112. DOI: https://doi.org/10.3390/molecules25010112

Rodríguez, F.; Caruana, P.; la Fuente, N.D.; Español, P.; Gámez, M.; Balart, J.; Llurba, E.; Rovira, R.; Ruiz, R.; Martín-Lorente, C.; et al. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules 2022, 12, 784. DOI: https://doi.org/10.3390/biom12060784

Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med. 2019, 4, e10143. DOI: https://doi.org/10.1002/btm2.10143

de Lázaro, I.; Mooney, D.J. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat. Mater. 2021, 11, 1469–1479. DOI: https://doi.org/10.1038/s41563-021-01047-7

Beiu, C.; Giurcaneanu, C.; Grumezescu, A.M.; Holban, A.M.; Popa, L.G.; Mihai, M.M. Nanosystems for Improved Targeted Therapies in Melanoma. J. Clin. Med. 2020, 9, 318. DOI: https://doi.org/10.3390/jcm9020318

Shan, X.; Gong, X.; Li, J.; Wen, J.; Li, Y.; Zhang, Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta. Pharm. Sin. B 2022, 12, 3028–3048. DOI: https://doi.org/10.1016/j.apsb.2022.02.025

Apalla, Z.; Lallas, A.; Sotiriou, E.; Lazaridou, E.; Ioannides, D. Epidemiological trends in skin cancer. Dermatol. Pract. Concept. 2017, 7, 1–6. DOI: https://doi.org/10.5826/dpc.0702a01

International Agency for Research on Cancer Cancer Today. Estimated Number of New Cases Worlwide in 2020, Melanoma of Skin, Both Sexes, All Ages (Global Cancer Observatory).

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. DOI: https://doi.org/10.3322/caac.21660

International Agency for Research on Cancer Cancer Today. Estimated Number of Deaths Worlwide in 2020, Melanoma of Skin, Both Sexes, All Ages (Global Cancer Observatory).

Silva, G.S.; Rosenbach, M. Climate change and dermatology: An introduction to a special topic, for this special issue. Int. J. Women’s Dermatol. 2021, 7, 3–7. DOI: https://doi.org/10.1016/j.ijwd.2020.08.002

Parker, E.R. The influence of climate change on skin cancer incidence—A review of the evidence. Int. J. Women’s Dermatol. 2021, 7, 17–27. DOI: https://doi.org/10.1016/j.ijwd.2020.07.003

International Agency for Research on Cancer Cancer Tomorrow. Estimated Number of New Cases from 2020 to 2040 of Melanoma of Skin.

International Agency for Research on Cancer Cancer Tomorrow. —Estimated Number of Deaths from 2020 to 2040 of Melanoma of Skin.

Wróbel, S.; Przybyło, M.; Stępień, E. The Clinical Trial Landscape for Melanoma Therapies. J. Clin. Med. 2019, 8, 368. DOI: https://doi.org/10.3390/jcm8030368

Dzwierzynski, W.W. Melanoma Risk Factors and Prevention. Clin. Plast. Surg. 2021, 48, 543–550. DOI: https://doi.org/10.1016/j.cps.2021.05.001

Le Clair, M.Z.; Cockburn, M.G. Tanning bed use and melanoma: Establishing risk and improving prevention interventions. Prev. Med. Rep. 2016, 3, 139–144. DOI: https://doi.org/10.1016/j.pmedr.2015.11.016

El Ghissassi, F.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens-part D: Radiation. Lancet Oncol. 2009, 10, 751–752. DOI: https://doi.org/10.1016/S1470-2045(09)70213-X

International Agency for Research on Cancer Cancer Today. Estimated Number of New Cases Worldwide in 2020, Melanoma of Skin, Both Sexes, Per Countries (Global Cancer Observatory).

Emri, G.; Paragh, G.; Tósaki, Á.; Janka, E.; Kollár, S.; Hegedűs, C.; Gellén, E.; Horkay, I.; Koncz, G.; Remenyik, É. Ultraviolet radiation-mediated development of cutaneous melanoma: An update. J. Photochem. Photobiol. B. Biol. 2018, 185, 169–175. DOI: https://doi.org/10.1016/j.jphotobiol.2018.06.005

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Solar and Ultraviolet Radiation. In Radiation—A Review of Human Carcinogens, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Galichet, L., Ed.; International Agency for Research on Cancer: Lyon, France, 2012; Volume 100D, pp. 35–90. ISBN 978-92-832-0136-6.

Brenner, M.; Hearing, V.J. The Protective Role of Melanin Against UV Damage in Human Skin. Photochem. Photobiol. 2008, 84, 539–549. DOI: https://doi.org/10.1111/j.1751-1097.2007.00226.x

Paluncic, J.; Kovacevic, Z.; Jansson, P.J.; Kalinowski, D.; Merlot, A.M.; Huang, M.L.H.; Lok, H.C.; Sahni, S.; Lane, D.J.R.; Richardson, D.R. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim. Biophys. Acta—Mol. Cell Res. 2016, 1863, 770–784. DOI: https://doi.org/10.1016/j.bbamcr.2016.01.025

International Agency for Research on Cancer Cancer Today. Estimated Number of New Skin Melanoma Cases Worldwide in 2020 for Both Sexes (Global Cancer Observatory).

Morgese, F.; Sampaolesi, C.; Torniai, M.; Conti, A.; Ranallo, N.; Giacchetti, A.; Serresi, S.; Onofri, A.; Burattini, M.; Ricotti, G.; et al. Gender Differences and Outcomes in Melanoma Patients. Oncol. Ther. 2020, 8, 103–114. DOI: https://doi.org/10.1007/s40487-020-00109-1

Bellenghi, M.; Puglisi, R.; Pontecorvi, G.; De Feo, A.; Carè, A.; Mattia, G. Sex and Gender Disparities in Melanoma. Cancers 2020, 12, 1819. DOI: https://doi.org/10.3390/cancers12071819

Orthaber, K.; Pristovnik, M.; Skok, K.; Perić, B.; Maver, U. Skin Cancer and Its Treatment: Novel Treatment Approaches with Emphasis on Nanotechnology. J. Nanomater. 2018, 94, 409–420.

Naik, P.P.; Farrukh, S.N. Influence of Ethnicities and Skin Color Variations in Different Populations: A Review. Skin Pharmacol. Physiol. 2021, 35, 65–76. DOI: https://doi.org/10.1159/000518826

Deng, L.; Xu, S. Adaptation of human skin color in various populations. Hereditas 2017, 155, 1–12. DOI: https://doi.org/10.1186/s41065-017-0036-2

Hessler, M.; Jalilian, E.; Xu, Q.; Reddy, S.; Horton, L.; Elkin, K.; Manwar, R.; Tsoukas, M.; Mehregan, D.; Avanaki, K. Melanoma Biomarkers and Their Potential Application for in Vivo Diagnostic Imaging Modalities. Int. J. Mol. Sci. 2020, 21, 9583. DOI: https://doi.org/10.3390/ijms21249583

Nasti, T.H.; Timares, L. MC1R, Eumelanin and Pheomelanin: Their Role in Determining the Susceptibility to Skin Cancer. Photochem. Photobiol. 2015, 91, 188–200. DOI: https://doi.org/10.1111/php.12335

Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Barsouk, A.; Sanguedolce, F.; Murray-Stewart, T. Epidemiology of Melanoma. Med. Sci. 2021, 9, 63. DOI: https://doi.org/10.3390/medsci9040063

Podlipnik, S.; Potrony, M.; Puig, S. Genetic markers for characterization and prediction of prognosis of melanoma subtypes: A 2021 update. Ital. J. Dermatol. Venereol. 2021, 156, 322–330. DOI: https://doi.org/10.23736/S2784-8671.21.06957-1

Zocchi, L.; Lontano, A.; Merli, M.; Dika, E.; Nagore, E.; Quaglino, P.; Puig, S.; Ribero, S. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management. J. Clin. Med. 2021, 10, 3760. DOI: https://doi.org/10.3390/jcm10163760

Potrony, M.; Badenas, C.; Aguilera, P.; Puig-Butille, J.A.; Carrera, C.; Malvehy, J.; Puig, S. Update in genetic susceptibility in melanoma. Ann. Transl. Med. 2015, 3, 210.

Ming, Z.; Lim, S.Y.; Kefford, R.F.; Rizos, H. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Pigment. Cell Melanoma Res. 2020, 33, 345–357. DOI: https://doi.org/10.1111/pcmr.12824

Craig, S.; Earnshaw, C.H.; Virós, A. Ultraviolet light and melanoma. J. Pathol. 2018, 244, 578–585. DOI: https://doi.org/10.1002/path.5039

O’Neill, C.H.; Scoggins, C.R. Melanoma. J. Surg. Oncol. 2019, 120, 873–881. DOI: https://doi.org/10.1002/jso.25604

Imbernón-Moya, A.; Podlipnik, S.; Malvehy, J.; Puig, S. Initial Evaluation of Patients with Pigmented Skin Lesions. Actas Dermosifiliogr. 2016, 107, 616–618. DOI: https://doi.org/10.1016/j.adengl.2016.06.016

Horrell, E.M.W.; Wilson, K.; D’Orazio, J.A. Melanoma—Epidemiology, Risk Factors, and the Role of Adaptive Pigmentation. In Melanoma—Current Clinical Management and Future Therapeutics; Murph, M., Ed.; IntechOpen: London, UK, 2015; ISBN 978-953-51-7237-6. DOI: https://doi.org/10.5772/58994

Coricovac, D.; Dehelean, C.; Moaca, E.A.; Pinzaru, I.; Bratu, T.; Navolan, D.; Boruga, O. Cutaneous melanoma-a long road from experimental models to clinical outcome: A review. Int. J. Mol. Sci. 2018, 19, 1566. DOI: https://doi.org/10.3390/ijms19061566

Betancourt, L.H.; Szasz, A.M.; Kuras, M.; Rodriguez Murillo, J.; Sugihara, Y.; Pla, I.; Horvath, Z.; Pawłowski, K.; Rezeli, M.; Miharada, K.; et al. The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. Cancers 2019, 11, 1981. DOI: https://doi.org/10.3390/cancers11121981

Wagstaff, W.; Mwamba, R.N.; Grullon, K.; Armstrong, M.; Zhao, P.; Hendren-Santiago, B.; Qin, K.H.; Li, A.J.; Hu, D.A.; Youssef, A.; et al. Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. Genes Dis. 2022, 9, 1608–1623. DOI: https://doi.org/10.1016/j.gendis.2022.04.004

Šitum, M.; Buljan, M.; Kolić, M.; Vučić, M. Melanoma-Clinical, Dermatoscopical, and Histopathological Morphological Characteristics. Acta Dermatovenerol. Croat. 2014, 22, 1–12.

Duncan, L.M.D. The Classification of Cutaneous Melanoma. Hematol. Oncol. Clin. N. Am. 2009, 23, 501–513 DOI: https://doi.org/10.1016/j.hoc.2009.03.013

Ammirati, C.T.; Hruza, G.J. Clinical presentations of cutaneous melanoma. Facial Plast. Surg. Clin. N. Am. 2005, 13, 33–46. DOI: https://doi.org/10.1016/j.fsc.2004.04.009

Nakamura, Y.; Fujisawa, Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr. Treat. Options Oncol. 2018, 19, 1–11. DOI: https://doi.org/10.1007/s11864-018-0560-y

Goydos, J.S.; Shoen, S.L. Acral lentiginous melanoma. In Cancer Treatment and Research; Kaufman, H.L., Mehnert, J.M., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2016; Volume 167, pp. 321–329. ISBN 978-3-319-22539-5. DOI: https://doi.org/10.1007/978-3-319-22539-5_14

Cabrera, R.; Recule, F. Unusual Clinical Presentations of Malignant Melanoma: A Review of Clinical and Histologic Features with Special Emphasis on Dermatoscopic Findings. Am. J. Clin. Dermatol. 2018, 19, 15–23. DOI: https://doi.org/10.1007/s40257-018-0373-6

Cormier, J.; Voss, R.; Woods, T.; Cromwell, K.; Nelson, K. Improving outcomes in patients with melanoma: Strategies to ensure an early diagnosis. Patient Relat. Outcome Meas. 2015, 6, 229. DOI: https://doi.org/10.2147/PROM.S69351

Greinert, R.; Boniol, M. Skin cancer—Primary and secondary prevention (information campaigns and screening)—With a focus on children & sunbeds. Prog. Biophys. Mol. Biol. 2011, 107, 473–476. DOI: https://doi.org/10.1016/j.pbiomolbio.2011.08.008

Fontanillas, P.; Alipanahi, B.; Furlotte, N.A.; Johnson, M.; Wilson, C.H.; Pitts, S.J.; Gentleman, R.; Auton, A. Disease risk scores for skin cancers. Nat. Commun. 2021, 12, 1–13. DOI: https://doi.org/10.1038/s41467-020-20246-5

Berwick, M.; Erdei, E.; Hay, J. Melanoma epidemiology and public health. Dermatol. Clin. 2009, 27, 205–214. DOI: https://doi.org/10.1016/j.det.2008.12.002

Abbasi, N.R.; Shaw, H.M.; Rigel, D.S.; Friedman, R.J.; McCarthy, W.H.; Osman, I.; Kopf, A.W.; Polsky, D. Early Diagnosis of Cutaneous Melanoma: Revisiting the ABCD Criteria. JAMA 2004, 292, 2771–2776. DOI: https://doi.org/10.1001/jama.292.22.2771

Dinnes, J.; Deeks, J.J.; Grainge, M.J.; Chuchu, N.; Ferrante di Ruffano, L.; Matin, R.N.; Thomson, D.R.; Wong, K.Y.; Aldridge, R.B.; Abbott, R.; et al. Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst. Rev. 2018, 12, CD013194. DOI: https://doi.org/10.1002/14651858.CD013194

Quaglino, P.; Fava, P.; Broganelli, P.; Burzi, L.; Marra, E.; Ribero, S.; Fierro, M.T. Epidemiology, Prevention and Clinical Diagnosis of Melanoma. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 7–16. ISBN 978-3-030-45347-3. DOI: https://doi.org/10.1007/978-3-030-45347-3_2

Ward, W.H.; Lambreton, F.; Goel, N.; Yu, J.Q.; Farma, J.M. Clinical Presentation and Staging of Melanoma. In Cutaneous Melanoma: Etiology and Therapy; Ward, W.H., Farma, J.M., Eds.; Codon Publications: Brisbane, Australia, 2017; pp. 79–89. ISBN 978-0-9944381-4-0. DOI: https://doi.org/10.15586/codon.cutaneousmelanoma.2017.ch6

Dorrell, D.N.; Strowd, L.C. Skin Cancer Detection Technology. Dermatol. Clin. 2019, 37, 527–536. DOI: https://doi.org/10.1016/j.det.2019.05.010

Gualco, M. Histopathological Examination: The Keystone of Treatment of Melanoma. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 27–37. ISBN 978-3-030-45347-3. DOI: https://doi.org/10.1007/978-3-030-45347-3_4

Osella-Abate, S.; Bertero, L.; Senetta, R.; Mariani, S.; Lisa, F.; Coppola, V.; Metovic, J.; Pasini, B.; Puig, S.S.; Fierro, M.T.; et al. TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. Cancers 2019, 11, 452. DOI: https://doi.org/10.3390/cancers11040452

Dalmasso, B.; Vanni, I.; Bruno, W.; Andreotti, V.; Pastorino, L.; Spagnolo, F.; Ghiorzo, P. Molecular Assessment in Patients with Melanoma: When and Why? In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 39–45. DOI: https://doi.org/10.1007/978-3-030-45347-3_5

Davis, L.E.; Shalin, S.C.; Tackett, A.J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 2019, 20, 1366–1379. DOI: https://doi.org/10.1080/15384047.2019.1640032

Hartman, R.I.; Lin, J.Y. Cutaneous Melanoma—A Review in Detection, Staging, and Management. Hematol. Oncol. Clin. N. Am. 2019, 33, 25–38. DOI: https://doi.org/10.1016/j.hoc.2018.09.005

Meng, X.; Chen, J.; Zhang, Z.; Li, K.; Li, J.; Yu, Z.; Zhang, Y. Non-invasive optical methods for melanoma diagnosis. Photodiagnosis Photodyn. Ther. 2021, 34, 102266. DOI: https://doi.org/10.1016/j.pdpdt.2021.102266

Spagnolo, F.; Boutros, A.; Croce, E.; Tanda, E.; Cecchi, F.; Queirolo, P. New Melanoma Staging: Prognostic Factors. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 47–53. ISBN 978-3-030-45347-3. DOI: https://doi.org/10.1007/978-3-030-45347-3_6

Gershenwald, J.E.; Scolyer, R.A.; Hess, K.R.; Sondak, V.K.; Long, G.V.; Ross, M.I.; Lazar, A.J.; Faries, M.B.; Kirkwood, J.M.; McArthur, G.A.; et al. Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J. Clin. 2017, 67, 472. DOI: https://doi.org/10.3322/caac.21409

Garbe, C.; Amaral, T.; Peris, K.; Hauschild, A.; Arenberger, P.; Basset-Seguin, N.; Bastholt, L.; Bataille, V.; del Marmol, V.; Dréno, B.; et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment—Update 2022. Eur. J. Cancer 2022, 170, 256–284. DOI: https://doi.org/10.1016/j.ejca.2022.04.018

Eddy, K.; Chen, S. Overcoming Immune Evasion in Melanoma. Int. J. Mol. Sci. 2020, 21, 8984. DOI: https://doi.org/10.3390/ijms21238984

Merlino, G.; Herlyn, M.; Fisher, D.E.; Bastian, B.C.; Flaherty, K.T.; Davies, M.A.; Wargo, J.A.; Curiel-Lewandrowski, C.; Weber, M.J.; Leachman, S.A.; et al. The state of melanoma: Challenges and opportunities. Pigment. Cell Melanoma Res. 2016, 29, 404–416. DOI: https://doi.org/10.1111/pcmr.12475

Michielin, O.; Atkins, M.B.; Koon, H.B.; Dummer, R.; Ascierto, P.A. Evolving impact of long-term survival results on metastatic melanoma treatment. J. Immunother. Cancer 2020, 8, e000948. DOI: https://doi.org/10.1136/jitc-2020-000948

Switzer, B.; Puzanov, I.; Skitzki, J.J.; Hamad, L.; Ernstoff, M.S. Managing Metastatic Melanoma in 2022: A Clinical Review. JCO Oncol. Pract. 2022, 18, 335–351. DOI: https://doi.org/10.1200/OP.21.00686

Grzywa, T.M.; Paskal, W.; Włodarski, P.K. Intratumor and Intertumor Heterogeneity in Melanoma. Transl. Oncol. 2017, 10, 956. DOI: https://doi.org/10.1016/j.tranon.2017.09.007

Ng, M.F.; Simmons, J.L.; Boyle, G.M. Heterogeneity in Melanoma. Cancers 2022, 14, 3030. DOI: https://doi.org/10.3390/cancers14123030

Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Available online: https://www.accessdata.fda.gov/scripts/cder/daf/

European Medicines Agency. Medicines Database. Available online: https://www.ema.europa.eu/en/medicines

Henriques, V.; Martins, T.; Link, W.; Ferreira, B.I. The Emerging Therapeutic Landscape of Advanced Melanoma. Curr. Pharm. Des. 2018, 24, 549–558. DOI: https://doi.org/10.2174/1381612824666180125093357

Kozovska, Z.; Gabrisova, V.; Kucerova, L. Malignant melanoma: Diagnosis, treatment and cancer stem cells. Neoplasma 2016, 63, 510–517. DOI: https://doi.org/10.4149/neo_2016_403

Garbe, C.; Amaral, T.; Peris, K.; Hauschild, A.; Arenberger, P.; Bastholt, L.; Bataille, V.; del Marmol, V.; Dréno, B.; Fargnoli, M.C.; et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment—Update 2019. Eur. J. Cancer 2020, 126, 159–177. DOI: https://doi.org/10.1016/j.ejca.2019.11.015

Joyce, K.M. Surgical Management of Melanoma. In Cutaneous Melanoma: Etiology and Therapy; Ward, W.H., Farma, J.M., Eds.; Codon Publications: Brisbane, Australia, 2017; pp. 91–100. ISBN 978-0-9944381-4-0. DOI: https://doi.org/10.15586/codon.cutaneousmelanoma.2017.ch7

Friedman, E.B.; Thompson, J.F. Continuing and new roles for surgery in the management of patients with stage IV melanoma. Melanoma Manag. 2018, 5, MMT03. DOI: https://doi.org/10.2217/mmt-2017-0024

Bello, D.M. Indications for the surgical resection of stage IV disease. J. Surg. Oncol. 2019, 119, 249–261. DOI: https://doi.org/10.1002/jso.25326

Enomoto, L.M.; Levine, E.A.; Shen, P.; Votanopoulos, K.I. Role of Surgery for Metastatic Melanoma. Curr. Manag. Melanoma 2021, 100, 127–139. DOI: https://doi.org/10.1016/j.suc.2019.09.011

Spagnolo, F.; Tanda, E.; Boutros, A.; Cecchi, F.; Queirolo, P. Medical Treatment of Melanoma: Adjuvant and Neoadjuvant Therapies. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 157–165. DOI: https://doi.org/10.1007/978-3-030-45347-3_16

Spagnolo, F.; Boutros, A.; Tanda, E.; Cecchi, F.; Queirolo, P. Systemic Treatment in Advanced Melanoma. In Current Management of Melanoma; Cafiero, F., De Cian, F., Eds.; Springer: Cham, Switzerland, 2021; pp. 167–174. ISBN 978-3-030-45347-3. DOI: https://doi.org/10.1007/978-3-030-45347-3_17

Pinho, J.O.; Matias, M.; Gaspar, M.M. Emergent nanotechnological strategies for systemic chemotherapy against melanoma. Nanomaterials 2019, 9, 1455. DOI: https://doi.org/10.3390/nano9101455

Shi, W. Radiation Therapy for Melanoma. In Cutaneous Melanoma: Etiology and Therapy; Ward, W.H., Farma, J.M., Eds.; Codon Publications: Brisbane, Australia, 2017; pp. 101–120. ISBN 978-0-9944381-4-0. DOI: https://doi.org/10.15586/codon.cutaneousmelanoma.2017.ch8

Sayan, A.; Plant, R.; Eccles, B.; Davies, C.; Ilankovan, V. Recent advances in the management of cutaneous malignant melanoma: Our case cohort. Br. J. Oral Maxillofac. Surg. 2021, 59, 534–545. DOI: https://doi.org/10.1016/j.bjoms.2020.11.008

United States National Institutes of Health. ClinicalTrials.gov Database. Available online: https://clinicaltrials.gov/

Wilson, M.A.; Schuchter, L.M. Chemotherapy for Melanoma. In Melanoma. Cancer Treatment and Research; Kaufman, H., Mehnert, J., Eds.; Springer: Cham, Switzerland, 2016; Volume 167, pp. 209–229. ISBN 978-3-319-22539-5. DOI: https://doi.org/10.1007/978-3-319-22539-5_8

Gupta, A.; Gomes, F.; Lorigan, P. The role for chemotherapy in the modern management of melanoma. Melanoma Manag. 2017, 4, 125. DOI: https://doi.org/10.2217/mmt-2017-0003

Luke, J.J.; Schwartz, G.K. Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma. Clin. Dermatol. 2013, 31, 290–297. DOI: https://doi.org/10.1016/j.clindermatol.2012.08.016

Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18, 158–166. DOI: https://doi.org/10.1200/JCO.2000.18.1.158

Gogas, H.J.; Kirkwood, J.M.; Sondak, V.K. Chemotherapy for metastatic melanoma. Cancer 2007, 109, 455–464. DOI: https://doi.org/10.1002/cncr.22427